Oxford BioDynamics
Oxford BioDynamics develops blood-based diagnostic tests and precision medicine tools using its proprietary 3D genomics platform.
The technology analyses chromosome conformation to identify epigenomic biomarkers linked to disease, prognosis and treatment response.
Commercial products include tests for immune checkpoint inhibitor response and prostate cancer detection, while its EpiSwitch Orion platform supports AI-driven target discovery and patient stratification for drug development.
Latest News
Oxford BioDynamics Extends Vulpes Payment Deadline on Placing to 30 October
Oxford BioDynamics has extended to 30 October the deadline for Vulpes Investment Management to pay the remaining £250,000 of its £500,000 subscription in the August placing. The company has received all other net proceeds and says the delay will not affect its financial position or prospects.
Oxford BioDynamics platform links five fatigue-related conditions
Oxford BioDynamics' EpiSwitch Orion platform has identified shared 3D genome regulatory networks across five distinct fatigue-related conditions — ME/CFS, long COVID, PTSD, rheumatoid arthritis, and multiple sclerosis — in a peer-reviewed study led by the University of East Anglia. Despite almost no overlap at the individual gene level, the conditions converged on common immune, inflammatory, metabolic, and neuroendocrine circuitry, demonstrating Orion's ability to surface biological insights from existing genomic data.
Oxford BioDynamics Names CEO Richard Compton to the Board
Oxford BioDynamics has appointed its Chief Executive Officer, Richard Compton, as an Executive Director on the board.